IJSR - International Journal of Scientific Research

Volume : VII, Issue : VIII, August - 2018

Dr Shikhar Dogra, Dr Siddharth Lamba, Dr Nidhi Kushwah, Dr Indira Sarin

In management of osteolytic lesions of bone definitive treatment involve intralesional excision and filling of the bone defect.1,2 Various material

such as autologous bone graft3, allogenic bone graft [4], [5], synthetic materials including calcium phosphate6, calcium hydroxy apatite7, have been

used with variable results. Allogenic Bone Graft (ABG) have got distinct advantage of being available in sufficient quantity without the risk of

donor site morbidity and doesn‘t warrant a second surgery for removal. From 2011 to 2013 , 8 consecutive benign osteolytic lesions (3 cases each of

of aneurysmal and simple bone cysts and 2 cases of Giant Cell Tumour) were treated by intralesional curettage and bone grafting using deep freezed

gamma irradiated allogenic bone graft either alone or in combination with autogenic bone graft/ bone marrow aspirate. All the patients were

randomly allocated to either vancomycin impregnated allogenic bone graft group (n=5) or simple allogenic bone graft group (n=3). The age range

of studied patients was from 14 to 43 years. Vancomycin impregnated allogenic bone graft appears to be a safe & effective filler, without any

systemic local and adverse effects, for bone defects secondary to benign osteolytic lesions. None of the patients develop postoperative infection.

All the eight osteolytic lesions in the study healed with the use of allogenic bone graft.